Maxygen, Inc.

Dna Twopointo Inc.

Dna2.0, Inc.

AT&T Intellectual Property I, LP

Novozymes A/s

Codexis Mayflower Holdings, LLC

Other

Archer Daniels Midland Company

Calysta, Inc.

Othair Prothena Limited

Allena Pharmaceuticals, Inc.

Novozymas Als

Mark D Welch

Jeremy S Minshull

Jon Edward Ness

Claes Gustafsson

Willem P C Stemmer

Phillip A Patten

Steven Henry Bass

Andreas Crameri

Sridhar Govindrajan

Kate Caves

Lorraine Joan Giver

Torben Vedel Borchert

Joel R Cherry

Maggie Lee

Sridhar Govindarajan

Brian S Carr

Joshua A Silverman

Robin A Emig

Matthew B Tobin

William Schroeder

Padmesh Venkitasubramanian

Joseph A Affholter

Effendi Leonard

Renee M Saville

Sun Ai Raillard

Arun Kandappan

Stanley Goldman

Jana Stumpe

Pascal Longchamp

Kevin White

Joseph Schutte

Robin McDaid Barbour

Tarlochan S Nijjar

Willem P Stemmer

Stephane J Jenne

Stephan Jenne

S Christopher Davis

Wagner Marcelo Zago

Jurgen Carsten Franz Knotzel

Frank Mikkelsen

Stefan Minning

Frédérique Bard

Danica Grujic

Earl Berner

Willem Pc Stemmer

Simon Christopher Davis

Niels Henrik Sorensen

Michael Skov

Kristina Robinson

Mark Magnusson

James D Rushing

Tina Sejersg&aring;rd Fan&oslash;

Tom Purcell

Claus Gustafsson

Jason Porter

John E Ness

Aditi R Deshpande

Will Schroeder

Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.

Anti-Aβ antibodies

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.

DNA vectors, transposons and transposases for eukaryotic genome modification

This disclosure provides epimerase enzymes useful for commercial scale production of allulose from fructose. The disclosed enzymes ('epimerase variants') are variants ofCGD1 xylose isomerase engineered to have improved catalytic activity of about 1.5- to 2-fold compared with the parent enzyme.

Epimerase enzymes and their use

The present disclosure provides nucleic acids and vectors for use with methanotrophic bacteria. Related host cells and methods for using such nucleic acids and vectors for expressing polypeptides or other genetic manipulation of methanotrophic bacteria are also provided.

Nucleic acids and vectors for regulated target gene expression in methanotrophic bacteria

Disclosed are recombinant mutanturicase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.

Recombinant uricase enzyme

Disclosed herein are three geneses of proteins herein established to exhibit a fructose to allulose epimerase activity that are useful for production of allulose from fructose at high temperatures and at low pH in the range of 4.5 to 6.0. Two of the three geneses descend phylogenetically from a common ancestral protein defined herein, and these geneses are distinguished from each other by different parental descendant proteins also defined herein. The proteins with high levels of sequence identity to the parental nodes defining from these two geneses generally exhibit higher levels of specific fructose to glucose epimerase activity than prior known fructose to allulose epimerases and exhibit such activity at low pH. A third genus is not defined by phylogenetic origin except by not descending from the same ancestor as the first two geneses but generally exhibit similar levels of fructose to allulose epimerase activities as prior art epimerases described to be useful for fructose to allulose conversion.

Genus of epimerase enzymes for conversion of fructose to allulose at high temperature and low pH

The present disclosure provides nucleic acids and vectors for use with methanotrophic bacteria. Related host cells and methods for using such nucleic acids and vectors for expressing polypeptides or other genetic manipulation of methanotrophic bacteria are also provided. In one aspect, the present disclosure is directed to a non-naturally occurring nucleic acid molecule, comprising (1) a promoter that is functional in a methanotrophic bacterium, and (2) a native or altered methanol dehydrogenase (MDH) ribosomal binding sequence, provided that when the promoter is an MDH gene promoter, the nucleic acid comprises an altered MDH ribosomal binding sequence.

Nucleic acids and vectors for use with methanotrophic bacteria

A method includes a processor for determining a life cycle of a first performance of a task flow for a telecommunication service order, determining that a performance of a first task within the first performance of the task flow has exceeded a threshold processing time, and determining that there is a problem with a first centralized system component in response to determining that the performance of the first task within the first performance of the task flow has exceeded the threshold processing time. The method may further include identifying the centralized system component for servicing when it is determined that there is a problem with the centralized system component.

Determining life-cycle of task flow performance for telecommunication service order

The present invention provides polynucleotide vectors for high expression of heterologous genes, and methods for constructing such vectors. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, but not limited to, gene expression, gene therapy, insertional mutagenesis, or gene discovery.

Enhanced nucleic acid constructs for eukaryotic gene expression

Growing community of inventors

Freemont, CA, United States of America

Mark D Welch